The multinational, observational CVD-REAL study recently showed that initiation of sodiumglucose co-transporter-2 inhibitors (SGLT-2i) was associated with significantly lower rates of death and heart failure vs other glucose-lowering drugs (oGLDs). This sub-analysis of the CVD-REAL study sought to determine the association between initiation of SGLT-2i vs oGLDs and rates of myocardial infarction (MI) and stroke. Medical records, claims and national registers from the USA, Sweden, Norway and Denmark were used to identify patients with T2D who newly initiated treatment with SGLT-2i (canagliflozin, dapagliflozin or empagliflozin) or oGLDs.
| INTRODUCTION
Despite advances in prevention, cardiovascular disease remains the leading cause of mortality and morbidity in patients with type 2 diabetes (T2D). Two large randomized controlled trials (RCTs) of sodium-glucose co-transporter-2 inhibitors (SGLT-2i; empagliflozin and canagliflozin) have shown significant reductions in major adverse cardiac events, as well as in hospitalizations for heart failure.
1,2 The rates of non-fatal myocardial infarction (MI) were numerically lower with both empagliflozin and canagliflozin vs placebo; the point estimates for non-fatal stroke numerically favoured placebo vs empagliflozin in the EMPA-REG OUT-COME trial, and canagliflozin vs placebo in the CANVAS Program, although none of these differences was statistically significant. 1, 2 Recently, the The Comparative Effectiveness of Cardiovascular
Outcomes (CVD-REAL) study, a multinational, observational study of over 300 000 patients, found that initiation of SGLT-2i was associated with a significant reduction in death and heart failure when compared to other glucose-lowering drugs (oGLDs). 3 Observational data from Nordic countries (CVD-REAL Nordic) has shown non-significant point estimates in favour of SGLT-2i for MI and stroke, using somewhat different statistical methods, and with dapagliflozin dominating the SGLT-2i group. 4, 5 However, the effects of SGLT-2i on atherothrombotic events in the larger CVD-REAL cohort, including patients from the USA, with a broader representation of SGLT-2i compounds, have not been explored previously. Accordingly, in this analysis of global CVD-REAL data, we sought to determine the association between initiation of SGLT-2i vs oGLDs and MI and stroke events.
| METHODS
The CVD-REAL study design has been described previously. 3 For this analysis, adult patients with T2D who newly initiated treatment with SGLT-2i (canagliflozin, dapagliflozin or empagliflozin) or oGLDs were identified from medical records, claims and national registers collected from 4 countries (USA, Sweden, Norway and Denmark). Because of small numbers of patients and events in Germany and the United Kingdom, we elected not to include data from these countries in this analysis. A non-parsimonious propensity score was developed separately within each country to predict the likelihood of receiving a prescription for an SGLT-2i, and patients were matched 1:1 in the 2 treatment groups. In the main on-treatment analysis, patients were followed from the index date (initiation of the SGLT-2i or oGLD) until completion of treatment, occurrence of an outcome event, death or censoring. The endpoints of interest were time to MI and stroke. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) for each endpoint were generated using Cox regression models, with inverse variance weighting for each country. In a sensitivity analysis, an intent-to-treat (ITT) approach was used, in which patients were followed after discontinuation of index treatment. Analyses of de-identified data were conducted in accordance with local laws and regulations, and received approvals from the respective Scientific/Ethics/Data Protection Committees.
| RESULTS
After propensity-score matching, 205 160 patients were included in the analysis (102 580 in each group), and baseline characteristics were well balanced between the 2 groups. Among participants, the mean age was 57 years, 43% were female, 14% had documented cardiovascular disease before SGLT-2i or oGLD initiation. In the SGLT-2i group, of the total exposure time, 49% of patients received dapagliflozin, 44% canagliflozin and 7% empagliflozin. There was significant geographical variation with regard to the specific SGLT-2i used, with canagliflozin used predominately (75%) in the USA, and dapagliflozin used predominately (90%) in Europe. In patients initiating treatment with oGLDs, the most commonly used classes were insulin (34%), dipeptidyl peptidase-4 (DPP-4) inhibitors (18%), sulfonylureas (17%), glucagon-like peptide-1 receptor agonists (14%) and metformin (12%).
For the on-treatment analysis, the mean follow-up time was 254 days in the SGLT-2i group and 232 days in the oGLD group. compounds. Collectively, our findings complement the results of the completed cardiovascular outcomes trials of SGLT-2i, and prior observational analyses, and offer additional reassurance with regard to the cardiovascular effects of SGLT-2i, specifically as it relates to ischaemic events, especially stroke, for which concerns had been raised previously based on a small numerical excess of stroke events with empagliflozin vs placebo, which was not statistically significant. 2 The results of our study should be considered in the context of several potential limitations. First, given the observational nature of the analyses, and despite robust statistical techniques, including 1:1 propensity matching, a possibility of residual, unmeasured confounding cannot be FIGURE 1 Event rates, unadjusted hazard ratios and 95% CIs for acute myocardial infarction (A) and stroke (B) in the on-treatment population, and for acute myocardial infarction (C) and stroke (D) in the ITT population. Abbreviations: ER, event rate; oGLD, other glucose-lowering drug; P-Y, person-years; SGLT-2i, sodium-glucose transporter-2 inhibitors definitively excluded. Second, despite a large number of accrued patientyears of follow up, the average duration of follow-up was relatively limited, as SGLT-2i use in real-world practice is still recent; longer-term follow-up will be needed to evaluate whether effects are sustained over time. Finally, given that CVD-REAL is a large, multinational pharmacoepidemiologic comparative effectiveness study, it was not designed to examine the potential mechanisms linking the use of SGLT-2i and associated cardiovascular benefits. However, it is highly unlikely that glucose lowering per se is behind the lower risk of cardiovascular events. As an example, prior analyses from the EMPA-REG OUTCOME trial have demonstrated little mediation effect of HbA1c on the cardiovascular benefits of empagliflozin. 6 Potential mechanisms may involve reductions in oxidative stress, improvement in endothelial function, neuro-hormonal modulation and anti-inflammatory effects, among others. [7] [8] [9] [10] [11] A metabolic hypothesis has also been proposed, suggesting that a shift in myocardial metabolism from glucose and free fatty acids to ketones may contribute to the cardiovascular benefits of SGLT-2i. 12 Importantly, this knowledge gap is being examined by mechanistic investigations across the SGLT-2i
class, with more information forthcoming in the near future. Editorial support was provided by Nicola Truss PhD of inScience Communications, Springer Healthcare, and was funded by AstraZeneca.
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